ClinicalTrials.gg
CompletedNCT01685359Updated Oct 28, 2022

PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant

A Phase 1 interventional study of Epoetin Alfa in Healthy, sponsored by Azidus Brasil. Completed at 1 site in Brazil. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-28.

Sponsored by Azidus Brasil · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

The hypothesis of this trial is that the test drug (Human Recombiant Epoetin - Blau) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ® - Janssen-Cilag) in healthy subjects following administration of multiple intravenous dose. The objective of this randomized, parallel, clinical trial is to evaluate the pharmacokinetic and pharmacodynamic profile of the test drug Human Reconbiant Epoetin produced by Blau Farmacêutica, compared to the comparator drug Eprex®, produced by Janssen-Cilag, by assessing plasma concentration of the drug and the reticulocyte count following a multiple intravenous administration during 4 weeks of 100 IU/kg in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Azidus Brasil is the lead sponsor of 80 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agree to all the purposes of the study by signing and dating the ;
  • Male, aged between 20 and 55 years, clinically healthy;
  • between 18.5 and 30;
  • between 13.8 and 15.4 g / dL and hematocrit between 41% and 49%;
  • VCM between 82 and 98, HBMC between 26 and 34, between 150,000 and 400,000 units per mL. and WBC between 3,500 to 10,500 units per ml and no atypical cells.
  • Human serum ferritin between 36-262 mcg / L;
  • Counting of reticulocytes in peripheral blood ≤ 3%;
  • Serum erythropoietin \< 30 mIU / mL.

Exclusion criteria

Exclusion Criteria:

  • Participation in clinical trials in the 12 months preceding the survey;
  • Body weight > 100 kg;
  • Presence of iron deficiency anemia;
  • Presence of pulmonary, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems diseases;
  • Acute disease in the period of 07 days before the beginning of the practical phase (administration of the drug) of the study;
  • Chronic administration of medications for hypertension, diabetes or any other disease that requires continuous use of any drug;
  • Hormone therapy in the period of 02 months preceding the beginning of the practical phase (administration of the drug) of the study;
  • Administration of any drug in the 02 weeks prior to the start of the practical period of the study;
  • Clinical history of or hereditary anemia;
  • Clinical history of chronic bleeding;
  • Clinical history of acute bleeding in the 30 days preceding the beginning of practical phase of the study (administration of the drug);
  • Clinical history of allergy of biological products derived from mammalian albumin or any component of the formulation;
  • Current or previous history (less than 12 months) of illicit drug abuse and / or tobacco and / or alcohol or having consumed alcohol within 48 hours prior to the practical study periods (administration of the drug);
  • Prior therapies with erythropoietin;
  • Albumin below 3.5 g/dL or higher than 4.8 g/dL;
  • Signs or clinical history of bone marrow aplasia;
  • History and clinical or laboratory liver disease;
  • History and clinical or laboratory nephropathy;
  • Principal Investigator of the study criteria.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Test Drug

    Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration

    Drug: Epoetin Alfa

  • Active comparator
    Eprex

    Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration

    Drug: Epoetin Alfa

Interventions

  • Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)

    Also known as: Eprex

06

What researchers measure

Primary outcomes

  1. rHuEPO Serum Concentration

    Time frame on days 1, 8, 19 and 22: -10min, 0h, 5min, 15min, 30min, 45min, 1,5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h and 12h after administration; Time frame on day 26: -10min, 0h, 5min, 15min, 30min, 45min, 1,5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h and 36h after last drug administration.

    Time frame: 1, 8, 15, 19, 22 and 26 days after first administration

  2. Plasma reticulocyte count

    Time frame on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26: 10 minutes before drug administration. Time frameon day 29: 72h +/- 2h after last drug administration.

    Time frame: 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 and 29 days after first administration of the drug.

07

Study locations

1 site
  • LAL Clinica
    Valinhos, Sao Paulo 13276-245, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in Oct 2013, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2012
First posted
Sep 14, 2012
StartActual
Feb 28, 2013
Primary completionActual
Oct 31, 2013
CompletionActual
Oct 31, 2013
Last update
Oct 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01685359
Lead sponsor
Azidus Brasil
Responsible party
Sponsor
First posted
Sep 14, 2012
Start date
Feb 28, 2013
Primary completion
Oct 31, 2013
Completion
Oct 31, 2013
Last update
Oct 28, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion